🟢 Kailera Therapeutics is trading 12% up in pre-market; no clear catalyst confirmed

Kailera Therapeutics is trading 11.98% up at $12.14 in pre-market, with no clear catalyst identified.

• Latest reported updates were Phase 1 data presented October 1 and completion of enrollment in its Phase 3 program; available coverage identifies no new October 6 announcement explaining the move.
• Major-index gains are all below 0.5%, so broad-market strength alone does not establish a cause. The move follows a 4.33% rise in the October 5 session, with no clear catalyst confirmed for either move.